Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Scopus)
10 Downloads (Pure)


Treatment of Guillain-Barre syndrome with a standard course of high-dose intravenous immunoglobulin ( IVIg) results in a variable clinical recovery which is associated with changes in serum IgG levels after treatment. The neonatal Fc-receptor protects IgG from degradation, and a genetic polymorphism in its promoter region that influences the expression of Fc-receptor, may in part explain the variation in IgG levels and outcome. This polymorphism was determined by polymerase chain reaction in a cohort of 257 patients with Guillain-Barre syndrome treated with IVIg. We could not demonstrate a relation between this polymorphism, the pharmacokinetics of IVIg, or the clinical course and outcome.
Original languageUndefined/Unknown
Pages (from-to)547-551
Number of pages5
JournalAnnals of Clinical and Translational Neurology
Issue number7
Publication statusPublished - 2016

Research programs

  • EMC MM-02-72-02
  • EMC MM-04-44-02

Cite this